Lipoprotein electrophoresis: clarification of lipid metabolism disorders

Lipoprotein electrophoresis is a laboratory technique in which lipoprotein particles are separated by their mobility in an electric field, most often in an agarose gel. Historically, this approach helped formulate the classical phenotypic classification of lipid metabolism disorders, but in modern practice, it is used significantly less frequently than standard lipidograms and direct quantitative tests. [1]

The main reason for this shift is that modern cardiometabolic assessment relies primarily on quantitative indicators of atherogenic particles and cardiovascular risk. Current reviews and consensus statements emphasize the importance of standard lipid profiles, apolipoprotein B, and lipoprotein A, while electrophoretic phenotyping has become a specialized tool for specific clinical situations. [2]

This doesn't mean the method has lost its value entirely. On the contrary, it remains useful in cases where standard lipid profile values fail to explain the underlying biology of the disorder. This primarily applies to suspected dysbetalipoproteinemia, or type III, as well as certain rare abnormal lipoproteins, such as lipoprotein X in cholestasis. [3]

The modern view of lipoprotein electrophoresis can be summarized as follows: it is not a screening test for mass use, but a clarifying study for complex, mixed, rare, and phenotypically non-obvious lipid metabolism disorders. It is in this capacity that it offers the greatest clinical benefit and helps avoid misinterpretations of standard lipidograms. [4]

Therefore, a new article on this topic should be built not around the old idea of "universal typing of all dyslipidemias," but around a more honest, modern framework: when a method is truly needed, what exactly it shows, where it is limited, and what tests should be added to it. This approach is much closer to real-world clinical practice in 2025-2026. [5]

Table 1. The current position of the method

Question	A modern answer
Is the method basic for all patients with dyslipidemia?	No, the standard lipid profile remains the basis.
Is it suitable for mass screening?	Usually no
Where the method is most useful	If type III, lipoprotein X, unusual mixed phenotypes are suspected
Does apolipoprotein B replace lipoprotein A?	No, but it complements them.
Is the method completely obsolete?	No, but it is niche and specialized.

The table summarizes current positions of laboratory catalogs, consensus statements on apolipoprotein B, and updated reviews on the phenotyping of dyslipidemias. [6]

How the study is performed and what exactly the laboratory sees

The classic test is performed on fasting serum. After applying the sample to an agarose gel, the lipoproteins are separated into zones based on their electrophoretic mobility, after which the bands are stained and assessed visually or densitometrically. This approach yields not so much an absolute particle count as a characteristic "pattern" of lipoprotein fraction distribution. [7]

A typical description distinguishes the start zone, pre-beta zone, slow pre-beta zone, beta zone, and alpha zone. These regions correspond, respectively, to chylomicrons, very low-density lipoproteins, intermediate-density remnant particles, low-density lipoproteins, and high-density lipoproteins. It is this comparison that underlies the phenotypic interpretation of the result. [8]

It is crucial to understand that this method remains qualitatively semi-quantitative. It helps identify the predominant type of abnormal lipid transport, but does not replace direct measurement of cholesterol, triglycerides, apolipoprotein B, or lipoprotein A. Therefore, an electrophoretic pattern alone without a lipid profile and clinical context may be insufficient for making treatment decisions. [9]

For the electrophoretic analysis itself, sample requirements are more stringent than for a typical primary lipid screening. Major laboratory catalogs specify that the patient must fast for approximately 12-15 hours, and the sample must be stored and transported according to specific guidelines. This is important because, for routine lipidograms, fasting is often not permitted these days, but for gel phenotyping, pre-analysis is still critical. [10]

Another practical issue is that this method is not available in all laboratories and has a longer turnaround time than a standard lipid profile. This slower and less universal workflow is precisely why it remains underutilized in everyday clinical practice, despite retaining diagnostic value in specific indications. [11]

Table 2. What do the main zones of electrophoresis mean?

Gel zone	Which faction is dominant?	What could this mean clinically?
At the start	Chylomicrons	Severe chylomicronemia, severe hypertriglyceridemia
Pre beta	Very low density lipoproteins	Hypertriglyceridemia, excess triglyceride-rich particles
Slow pre-beta	Residual particles, including those of intermediate density	Suspected of Remnant Rich States
Beta	Low-density lipoproteins	Predominance of cholesterol-rich atherogenic particles
Alpha	High-density lipoproteins	Protective fraction, assessed in conjunction with the lipidogram
Wide beta band	Mixed beta and pre-beta zone	Dysbetalipoproteinemia is possible, but the sign is not absolutely specific

The table is based on the description of migration zones in modern textbooks and reference sources, including reviews of intermediate lipoproteins and specialized materials on dysbetalipoproteinemia. [12]

When research is really indicated

The most common indication is mixed dyslipidemia, in which total cholesterol and triglycerides are simultaneously elevated, and a standard lipidogram makes it difficult to determine which atherogenic particles predominate. In such situations, electrophoresis can provide structural information about the disorder's phenotype and help guide further investigation. [13]

This method is especially valuable when type III dyslipoproteinemia is suspected. This condition is associated with the accumulation of cholesterol-rich remnant particles and often remains underdiagnosed if the physician relies solely on a standard lipid profile. Historically, a broad beta band was sought for this condition, although diagnostics have now become more comprehensive. [14]

Another important indication is suspected lipoprotein X in patients with cholestasis and unusually high cholesterol. This is a rare but clinically very important situation, as lipoprotein X can mimic atherogenic hypercholesterolemia, although the pathophysiology and treatment strategies are quite different. In this context, electrophoresis helps to avoid overestimating the role of standard lipid-lowering drugs and promptly shift attention to liver or biliary tract disease. [15]

The method can also be used in cases of severe hypertriglyceridemia and suspected chylomicronemia, particularly if the distinction between types I and V is questionable. However, in this case, clinical urgency is often determined not by the phenotype itself, but by the risk of pancreatitis and the severity of the triglyceride elevation, so treatment should not be delayed solely for the sake of electrophoretic clarification. [16]

In contrast, for the average outpatient with moderately elevated cholesterol, no mixed phenotype, no severe hypertriglyceridemia, no cholestasis, and no suspicion of a rare hereditary syndrome, electrophoretic lipoprotein analysis is generally not necessary. In most such cases, a standard lipid profile, an assessment of overall cardiovascular risk, and, if indicated, apolipoprotein B and lipoprotein A levels will already provide the answer. [17]

Table 3. When the test is needed and when it is usually not

Clinical situation	Electrophoresis is usually needed	Why
Mixed dyslipidemia with high cholesterol and triglycerides	Yes	Helps to clarify the phenotype of particles
Suspected type III	Yes	The rich design of the remnant can be confirmed
Cholestasis with unusually high cholesterol	Yes	It is necessary to exclude lipoprotein X
Severe hypertriglyceridemia	Sometimes	Specifies the phenotype, but treatment is determined by urgency
Simple isolated hypercholesterolemia	Usually no	Standard tests and risk assessment are sufficient
Mass preventive screening	No	The method is too specialized

The table reflects the current distribution of indications between standard lipid diagnostics and specialized phenotyping. [18]

How to interpret the results and where errors most often occur

The most well-known finding in type III is a broad beta band, that is, an extended zone between beta and pre-beta. However, current literature emphasizes that this feature is neither sufficiently sensitive nor sufficiently specific. A 2025 review indicated that a broad beta band occurs in less than half of patients and can also appear in other conditions. [19]

Therefore, the diagnosis of dysbetalipoproteinemia today is not based on a single gel image. A more modern approach is to first identify mixed dyslipidemia, then assess the cholesterol ratio of all atherogenic particles, except high-density lipoproteins, to apolipoprotein B, and only then confirm the diagnosis with genetic testing, ultracentrifugation, or electrophoresis. In one algorithm, this three-step approach demonstrated high accuracy. [20]

An important nuance is that classical Fredrickson phenotyping remains largely a specialized and educational language of description. For most phenotypes, except for type III, algorithms based on standard lipidograms have already been proposed that correlate well with electrophoresis and beta-quantitative data. This is another reason why electrophoresis should not be considered a mandatory first step. [21]

A common misconception with lipoprotein X is that extremely high cholesterol is mistakenly interpreted as a normal accumulation of low-density lipoproteins. In fact, lipoprotein X is primarily associated with cholestasis, can give the false impression of an atherogenic profile, and requires treatment of the underlying disease rather than standard intensification of lipid-lowering therapy at any cost. [22]

Finally, interpretation of the result must always take into account the clinical context. Residual triglyceride-rich particles are inherently atherogenic, and severe hypertriglyceridemia can be associated not only with the risk of atherosclerosis but also with the risk of pancreatitis. Therefore, the electrophoretic pattern cannot be interpreted in isolation from symptoms, medical history, comorbidities, and standard biochemical parameters. [23]

Table 4. How to read basic patterns

Pattern	The most likely explanation	Limitations of interpretation
Wide beta band	Suspected type III, remnant-rich particles	The symptom does not occur in all patients and is not absolutely specific.
Enhanced pre-beta zone	Excess very low density lipoproteins	Often found in hypertriglyceridemia of various origins
The strip at the start	Chylomicrons	An assessment of the severity of hypertriglyceridemia and the risk of pancreatitis is needed.
Unusual pericathode or peristartal abnormal zone in cholestasis	Lipoprotein X	Requires connection with liver pathology
Predominant beta zone	Excess low-density lipoproteins	Often a standard lipidogram without electrophoresis is sufficient

The table is based on modern reviews of type III, lipoprotein X, and laboratory descriptions of electrophoretic zones. [24]

Limitations of the method and what analyses are used to supplement it today

The first and foremost limitation of the method is its limited sensitivity and specificity. The most illustrative example is type III dyslipoproteinemia, where the broad beta band alone can be missed or, conversely, overestimated. Therefore, modern diagnostics increasingly rely on a combination of clinical data, apolipoprotein B, calculated ratios, and genetic confirmation. [25]

The second limitation is that the method does not provide a complete quantitative assessment of atherogenic load. In many situations, apolipoprotein B and cholesterol of all atherogenic particles, except high-density lipoproteins, are better at predicting cardiovascular risk. The National Lipid Association consensus states that when there is a discrepancy between low-density lipoprotein cholesterol and apolipoprotein B, risk is often better reflected by apolipoprotein B or cholesterol of all atherogenic particles, except high-density lipoproteins. [26]

The third limitation is availability. Many clinical laboratories no longer routinely perform electrophoresis and ultracentrifugation, so the clinician often has to construct a phenotypic hypothesis based on a standard lipid profile and additional quantitative markers. This is clearly noted in the current expert consensus on apolipoprotein B. [27]

The fourth limitation is preanalytics. Fasting is often no longer required for routine primary lipid screening, but fasting is still desirable for electrophoretic phenotyping. Mixing these two approaches can lead to confusion: the physician may decide that any lipid analysis requires strict fasting, which is incorrect, or, conversely, that blood can be donated after a meal for electrophoresis, which is also incorrect. [28]

Therefore, in 2026, it makes more sense to consider electrophoretic lipoprotein analysis as an additional diagnostic layer. The baseline is a standard lipid profile, followed by apolipoprotein B, lipoprotein A, and additional calculated indicators if necessary, and electrophoresis for cases where phenotypic confirmation of a rare or controversial pattern is needed. This is the most rational modern model. [29]

Table 5. What supplements or replaces electrophoresis in routine practice today?

Method	What does it give?	When it is especially useful
Standard lipidogram	Basic screening and assessment of the severity of the disorder	Almost all patients
Apolipoprotein B	Number of atherogenic particles	In case of discrepancies in indicators, diabetes, hypertriglyceridemia, metabolic syndrome
Cholesterol of all atherogenic particles except high-density lipoproteins	Integral load of atherogenic particles	When LDL cholesterol is insufficient to assess risk
Lipoprotein A	Inherited additional risk	Usually at least once in adulthood
Genetic testing	Confirmation of hereditary phenotype	If type III and other hereditary syndromes are suspected
Lipoprotein electrophoresis	Phenotypic pattern of fractions	In rare, mixed and controversial cases

The table reflects the current redistribution of roles between routine and specialized lipid tests. [30]

Practical clinical value of the method

In practice, the study is most useful when the physician's question is not "does the patient have dyslipidemia?" but "which specific type of atherogenic particles is dominant and why the standard lipidogram appears unusual." In such cases, the electrophoretic pattern allows one to move from a set of numbers to a more understandable pathophysiological model. [31]

If a patient has significantly elevated cholesterol and triglycerides simultaneously, and the clinical picture suggests type III, it is logical to supplement the examination with apolipoprotein B and an assessment of the cholesterol ratio of all atherogenic particles, except high-density lipoproteins, to apolipoprotein B. If the ratio is suspicious, the next step is genetic verification and, if possible, confirmatory phenotyping. In this scheme, electrophoresis is not used in isolation, but as part of a step-by-step algorithm. [32]

If a patient has cholestasis, severe liver disease, sharply elevated cholesterol, and a strange discrepancy between the clinical picture and the usual perception of risk, the method helps to consider lipoprotein X. This is especially important because lipoprotein X is associated not so much with atherosclerosis as with complications of cholestatic disease itself and with laboratory confusion when interpreting the lipid profile. [33]

If severe hypertriglyceridemia predominates, the primary goal is to reduce the risk of pancreatitis and identify the causes of chylomicronemia. Electrophoresis may be useful in this situation, but it should not delay urgent treatment decisions, especially if triglycerides are very high and the patient is symptomatic. Phenotype is important here, but the clinical priority remains patient safety. [34]

The overall practical role of this method today appears to be as follows: it is a good specialized test for the accurate recognition of rare and mixed lipoprotein syndromes, but a poor candidate for a universal test "for everyone." The more precisely this boundary is understood, the lower the risk of both underdiagnosis of rare phenotypes and unnecessary prescription of a complex test where it does not change patient management. [35]

Table 6. Practical route after receiving an unusual lipid profile

Situation	The next logical step
High cholesterol without marked hypertriglyceridemia	Standard risk assessment, search for familial hypercholesterolemia, if necessary apolipoprotein B and lipoprotein A
High cholesterol and high triglycerides	Consider mixed phenotype, add apolipoprotein B, consider electrophoresis
Suspected type III	Assess clinical features, apolipoprotein B, appropriate ratio, then confirm phenotype and genetics
Cholestasis and very high cholesterol	Exclude lipoprotein X
Very high triglycerides	Urgently assess the risk of pancreatitis, look for chylomicronemia, use electrophoresis as a clarifying test
Unclear discrepancy between lipidogram and clinical picture	Re-examine quantitative markers and consider specialized phenotyping

The table is based on current algorithms for type III, the apolipoprotein B consensus, and reviews of rare lipoprotein conditions.[36]

Frequently Asked Questions

Does every person with high cholesterol need electrophoretic lipoprotein analysis?
No. In most cases, a standard lipid profile and assessment of overall cardiovascular risk are sufficient. Electrophoresis is usually needed for mixed, rare, or phenotypically unclear disorders. [37]

Can electrophoresis alone diagnose type III?
No. A broad beta band is a useful guide, but it is neither sufficiently sensitive nor sufficiently specific. Modern diagnosis is based on a combination of phenotype, apolipoprotein B, predictive criteria, and confirmatory tests. [38]

What is more important for prognosis today: electrophoresis or apolipoprotein B?
Apolipoprotein B is often more important for assessing atherogenic load and risk. Electrophoresis provides a phenotypic picture, while apolipoprotein B helps quantify the number of atherogenic particles. These are different but complementary tasks. [39]

Is it necessary to take this test strictly on an empty stomach?
For electrophoretic analysis, yes; approximately 12-15 hours of fasting is usually recommended. For a standard initial lipidogram, such strictness is not always necessary, and it is this distinction that is important to understand. [40]

Can the test help with cholestasis?
Yes. In rare cases, it can help identify lipoprotein X, which can cause very high cholesterol and mislead a standard lipid profile. [41]

If the lab doesn't perform electrophoresis, is that critical?
Not always. For most patients, a standard lipid profile, apolipoprotein B, and other quantitative tests are sufficient. The lack of electrophoresis becomes a problem primarily when a rare phenotype is suspected, especially type III or lipoprotein X. [42]

Can electrophoresis be replaced by modern computational algorithms?
For many phenotypes, the answer is partially yes. Algorithms based on standard lipidograms can recognize most classical phenotypes, but type III still requires separate clarification. [43]

What is the main conclusion for the editorial revision of the article?
The main conclusion is this: electrophoretic analysis of lipoproteins should not be described as a universal method for all lipid metabolism disorders, but as a specialized phenotypic test, especially valuable for type III, lipoprotein X, and complex mixed conditions. This presentation is currently the most medically accurate. [44]